The Hidden Role of Neuropeptides in Asthma: How Nerve Chemicals Drive Airway Inflammation
Neuropeptides like substance P, VIP, and CGRP play opposing roles in asthma — some drive inflammation and bronchoconstriction while others protect against it — opening new drug target possibilities.
Quick Facts
What This Study Found
Neuropeptides play a significant and underappreciated role in asthma beyond traditional inflammatory mechanisms. The airway epithelium contains pulmonary neuroendocrine cells that release neuropeptides including substance P (SP), neurokinin A (NKA), vasoactive intestinal peptide (VIP), CGRP, neuropeptide Y (NPY), and orphanin FQ (N/OFQ) after allergen exposure.
These neuropeptides have opposing effects: SP, NKA, and serotonin drive inflammation (promoting chemokine synthesis in eosinophils, mast cells, and neutrophils), while VIP and N/OFQ provide anti-inflammatory and bronchodilatory effects. CGRP and acetylcholine have dual roles depending on which receptor pathway is activated — for example, ACh acting on M3 receptors causes bronchoconstriction and mucus overproduction, while ACh acting on α7nAChR receptors on ILC2 cells actually reduces inflammation.
Experimental NK1R/NK2R antagonists and exogenous VIP administration have decreased inflammatory mediators in studies, suggesting that targeting neuropeptide pathways could be a novel therapeutic approach for asthma.
Key Numbers
6+ neuropeptides involved · SP-NK1R axis promotes eosinophil/mast cell chemokines · VIP-VPAC1 axis = bronchodilation · CGRP-RAMP1 enhances Th2/Th9 responses · ACh-α7nAChR reduces TNF-α, IL-1, IL-6
How They Did This
Narrative review published in Frontiers in Cell and Developmental Biology, synthesizing evidence on the roles of neurotransmitters and neuropeptides in asthma pathophysiology, their receptor pathways, and potential therapeutic applications.
Why This Research Matters
Most asthma research focuses on immune cells and inflammatory pathways, but the nervous system's contribution through neuropeptides is often overlooked. This review shows that neuropeptides are not just bystanders — they actively drive bronchoconstriction, mucus production, and immune cell recruitment. Understanding these pathways opens up entirely new drug targets for asthma, particularly for patients who don't respond well to conventional corticosteroid therapy.
The Bigger Picture
The neuroimmune connection in asthma represents a frontier where peptide biology meets respiratory medicine. While current asthma drugs target inflammation (corticosteroids) or airway constriction (bronchodilators), neuropeptide-targeted therapies could address both simultaneously. This is part of a broader recognition that neuropeptides are key regulators of immune responses throughout the body, not just in the brain.
What This Study Doesn't Tell Us
Narrative review without systematic search methodology. Much of the neuropeptide research in asthma comes from animal models, with limited human clinical trial data for neuropeptide-targeted therapies. The therapeutic potential of NK1R/NK2R antagonists and VIP is based largely on preclinical and early-phase studies.
Questions This Raises
- ?Could VIP inhalation therapy provide bronchodilation and anti-inflammatory effects simultaneously for treatment-resistant asthma?
- ?Would NK1R antagonists (substance P blockers) reduce asthma exacerbations in patients with neurogenic inflammation?
- ?How do neuropeptide profiles differ between asthma phenotypes, and could they be used for precision treatment selection?
Trust & Context
- Key Stat:
- 6+ neuropeptides involved At least six distinct neuropeptides are released in asthmatic airways after allergen exposure, with opposing pro- and anti-inflammatory effects
- Evidence Grade:
- Published in Frontiers in Cell and Developmental Biology, a peer-reviewed open-access journal. The review provides a comprehensive overview of neuropeptide pathways in asthma but much of the therapeutic evidence cited is preclinical rather than from human trials.
- Study Age:
- Published in 2021. The neuropeptide pathways described remain relevant, though the therapeutic landscape continues to evolve with newer peptide-based approaches.
- Original Title:
- Neuroimmune Pathophysiology in Asthma.
- Published In:
- Frontiers in cell and developmental biology, 9, 663535 (2021)
- Authors:
- Pavón-Romero, Gandhi F, Serrano-Pérez, Nancy Haydée, García-Sánchez, Lizbeth, Ramírez-Jiménez, Fernando, Terán, Luis M
- Database ID:
- RPEP-05673
Evidence Hierarchy
Frequently Asked Questions
How do neuropeptides affect asthma?
Specialized cells in the airways release neuropeptides when triggered by allergens. Some — like substance P and neurokinin A — worsen asthma by promoting inflammation, recruiting immune cells, and tightening airways. Others — like VIP and orphanin FQ — have the opposite effect, relaxing airways and reducing inflammation. The balance between these opposing neuropeptide signals helps determine asthma severity.
Could neuropeptide-targeting drugs treat asthma?
Early research suggests yes. Experimental drugs that block substance P receptors (NK1R antagonists) and inhaled VIP have reduced inflammatory markers in studies. Some existing asthma medications like anticholinergics already work by blocking neuropeptide pathways. Purpose-designed neuropeptide therapies could offer new options for patients who don't respond to conventional treatments.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-05673APA
Pavón-Romero, Gandhi F; Serrano-Pérez, Nancy Haydée; García-Sánchez, Lizbeth; Ramírez-Jiménez, Fernando; Terán, Luis M. (2021). Neuroimmune Pathophysiology in Asthma.. Frontiers in cell and developmental biology, 9, 663535. https://doi.org/10.3389/fcell.2021.663535
MLA
Pavón-Romero, Gandhi F, et al. "Neuroimmune Pathophysiology in Asthma.." Frontiers in cell and developmental biology, 2021. https://doi.org/10.3389/fcell.2021.663535
RethinkPeptides
RethinkPeptides Research Database. "Neuroimmune Pathophysiology in Asthma." RPEP-05673. Retrieved from https://rethinkpeptides.com/research/pavon-romero-2021-neuroimmune-pathophysiology-in-asthma
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.